# OnCo record paper-orient-4-sintilimab-nk-t-cell-lymphoma-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-orient-4-sintilimab-nk-t-cell-lymphoma-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-orient-4-sintilimab-nk-t-cell-lymphoma-2021" ;
  schema:name "Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)"@en ;
  schema:alternateName "ORIENT-4"@en, "Tao 2021"@en ;
  schema:description "The report of the Chinese trial in which the PD-1 antibody sintilimab produced responses in 75 per cent of people whose NK/T-cell lymphoma had relapsed after asparaginase chemotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-orient-4-sintilimab-nk-t-cell-lymphoma-2021/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41392-021-00768-0>, <https://pubmed.ncbi.nlm.nih.gov/34702811/>, <https://europepmc.org/article/MED/34702811> ;
  onco:tag "lymphoma-evidence-entities" ;
  schema:sameAs <https://doi.org/10.1038/s41392-021-00768-0> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Tao R, Fan L, Song Y, et al." ;
  onco:cancers <https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/sintilimab/> ;
  onco:trials <https://onco.cc/trials/orient-4/> .